Compare SHASUN PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA AUROBINDO PHARMA SHASUN PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 123.9 19.8 625.3% View Chart
P/BV x 8.5 4.3 199.0% View Chart
Dividend Yield % 0.2 0.2 95.0%  

Financials

 SHASUN PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
AUROBINDO PHARMA
Mar-19
SHASUN PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs94830 11.3%   
Low Rs46527 8.7%   
Sales per share (Unadj.) Rs214.2333.9 64.1%  
Earnings per share (Unadj.) Rs5.340.4 13.2%  
Cash flow per share (Unadj.) Rs15.851.8 30.6%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %1.40.4 388.3%  
Book value per share (Unadj.) Rs53.3237.1 22.5%  
Shares outstanding (eoy) m56.62585.91 9.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.0 16.1%   
Avg P/E ratio x13.116.8 77.9%  
P/CF ratio (eoy) x4.413.1 33.7%  
Price / Book Value ratio x1.32.9 45.8%  
Dividend payout %18.76.2 302.5%   
Avg Mkt Cap Rs m3,958397,569 1.0%   
No. of employees `000NA17.9 0.0%   
Total wages/salary Rs m2,16425,849 8.4%   
Avg. sales/employee Rs ThNM10,956.9-  
Avg. wages/employee Rs ThNM1,447.7-  
Avg. net profit/employee Rs ThNM1,324.3-  
INCOME DATA
Net Sales Rs m12,127195,636 6.2%  
Other income Rs m2291,553 14.8%   
Total revenues Rs m12,356197,189 6.3%   
Gross profit Rs m1,00939,519 2.6%  
Depreciation Rs m5946,680 8.9%   
Interest Rs m4152,626 15.8%   
Profit before tax Rs m23031,767 0.7%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m-737,269 -1.0%   
Profit after tax Rs m30223,645 1.3%  
Gross profit margin %8.320.2 41.2%  
Effective tax rate %-31.722.9 -138.4%   
Net profit margin %2.512.1 20.6%  
BALANCE SHEET DATA
Current assets Rs m6,884153,645 4.5%   
Current liabilities Rs m8,456120,429 7.0%   
Net working cap to sales %-13.017.0 -76.3%  
Current ratio x0.81.3 63.8%  
Inventory Days Days62135 45.6%  
Debtors Days Days10864 168.9%  
Net fixed assets Rs m4,970103,909 4.8%   
Share capital Rs m113586 19.3%   
"Free" reserves Rs m2,875138,322 2.1%   
Net worth Rs m3,020138,908 2.2%   
Long term debt Rs m1,8171,800 101.0%   
Total assets Rs m13,347264,544 5.0%  
Interest coverage x1.613.1 11.9%   
Debt to equity ratio x0.60 4,645.0%  
Sales to assets ratio x0.90.7 122.9%   
Return on assets %5.49.9 54.1%  
Return on equity %10.017.0 58.8%  
Return on capital %13.323.8 55.9%  
Exports to sales %46.449.6 93.4%   
Imports to sales %14.218.8 75.9%   
Exports (fob) Rs m5,62297,091 5.8%   
Imports (cif) Rs m1,72836,741 4.7%   
Fx inflow Rs m5,84397,316 6.0%   
Fx outflow Rs m2,17340,589 5.4%   
Net fx Rs m3,66956,727 6.5%   
CASH FLOW
From Operations Rs m39816,220 2.5%  
From Investments Rs m-1,635-28,768 5.7%  
From Financial Activity Rs m1,30919,191 6.8%  
Net Cashflow Rs m716,656 1.1%  

Share Holding

Indian Promoters % 39.2 54.1 72.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 8.0 45.3%  
FIIs % 17.6 27.7 63.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.2 388.2%  
Shareholders   20,750 69,601 29.8%  
Pledged promoter(s) holding % 12.3 8.6 143.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   PANACEA BIOTECH  BIOCON   FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 424 Points Higher; Sun Pharma and UPL Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

SHILPA MEDICARE Share Price Up by 5%; BSE HEALTHCARE Index Up 3.0% (Market Updates)

May 5, 2021 | Updated on May 5, 2021

SHILPA MEDICARE share price is trading up by 5% and its current market price is Rs 443. The BSE HEALTHCARE is up by 3.0%. The top gainers in the BSE HEALTHCARE Index are SHILPA MEDICARE (up 5.3%) and APOLLO HOSPITALS (up 5.1%). The top losers are SYNGENE INTERNATIONAL (down 0.1%) and DR. LAL PATHLABS (down 0.3%).

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - TORRENT PHARMA COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS